TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35138568

Group type: COMPARATOR
Intervention: SRP alone (group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SRP+low‐level laser therapy (LLLT) with Nd:YAG laser (group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SRP+pocket debridement with Nd:YAG laser (group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SRP+combined pocket debridement and LLLT with Nd:YAG laser (group 4)
Number of subjects: 80
Study: 32965593

Group type: EXPERIMENTAL
Intervention: Active (real) tRNS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tRNS
Number of subjects: 10
Study: 36071624

Group type: EXPERIMENTAL
Intervention: Video call group (VCG: standard care + video call)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (CG: standard care)
Number of subjects: 72
Study: 33098716

Group type: EXPERIMENTAL
Intervention: Rhinitis in the last 12 months
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Allergic conjunctivitis in the last 12 months
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Eczema in the last 12 months
Number of subjects: 1700
Study: 32854824

Group type: EXPERIMENTAL
Intervention: Back-support exoskeletons (BSEs)
Number of subjects: 18
Study: 34697249

Group type: EXPERIMENTAL
Intervention: 100% arterial occlusion pressure
Number of subjects: 22

Group type: COMPARATOR
Intervention: 150% arterial occlusion pressure
Number of subjects: 22
Study: 33723015

Group type: EXPERIMENTAL
Intervention: Recovery of LVEF at 4 months
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Recovery of LVEF at 2 years
Number of subjects: 932
Study: 33066856

Group type: EXPERIMENTAL
Intervention: Turmacin 0.5 g
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Turmacin 1 g
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 33356569

Group type: EXPERIMENTAL
Intervention: Multimodal pain regimen (pregabalin, celecoxib, acetaminophen, regional block with oxycodone for breakthrough pain)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional pain management (regional block, acetaminophen, oxycodone)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Multimodal pain regimen
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional pain management
Number of subjects: 42
Study: 35644038

Group type: EXPERIMENTAL
Intervention: Family based treatments (FBTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study: 34948702

Group type: EXPERIMENTAL
Intervention: Rigid surface group (RsG)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sand surface group (SsG)
Number of subjects: 17
Study: 35061644

Group type: EXPERIMENTAL
Intervention: Oblique-type superior pubic ramus fractures
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Posterior-only and combined anterior and posterior fixation configurations
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transverse-type fractures
Number of subjects: 10
Study: 33010766

Group type: EXPERIMENTAL
Intervention: Trochlear resurfacing with HemiCAP® PF Classic implant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medial UKA without trochlear resurfacing
Number of subjects: 60
Study: 34994291

Group type: EXPERIMENTAL
Intervention: Demonstration method
Number of subjects: 90

Group type: COMPARATOR
Intervention: Verbal training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Training with written materials
Number of subjects: 90
Study: 36175532

Group type: EXPERIMENTAL
Intervention: Modified nasopharyngeal oxygen therapy (Group Naso)
Number of subjects: 84

Group type: COMPARATOR
Intervention: High-flow nasal oxygen therapy (Group HFNO)
Number of subjects: 84
Study: 33454393

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with routine oral hygiene maintenance instructions (OHMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine oral hygiene maintenance instructions (OHMI) alone
Number of subjects: 0
Study: 32164702

Group type: EXPERIMENTAL
Intervention: WP + HMB
Number of subjects: 16

Group type: COMPARATOR
Intervention: WP + PLA
Number of subjects: 16
Study: 35410799

Group type: EXPERIMENTAL
Intervention: 7 Tesla MRI
Number of subjects: 7

Group type: COMPARATOR
Intervention: 3 Tesla MRI
Number of subjects: 7
Study: 33761206

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vaccine regimen (2704 participants)
Number of subjects: 5404

Group type: COMPARATOR
Intervention: Placebo (2700 participants)
Number of subjects: 5404
Study: 35056316

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Stimulation (DRGS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of SCS and DRGS (SCS+DRGS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tonic conventional stimulation
Number of subjects: 66
Study: 32704082

Group type: EXPERIMENTAL
Intervention: Nutritional support plus green-banana biomass (40 g) (n=21)
Number of subjects: 39
Study: 33400390

Group type: EXPERIMENTAL
Intervention: UC-MSC treatment (100 ± 20 × 10^6 UC-MSCs, two intravenous infusions at day 0 and 3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: UC-MSC treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (vehicle solution, two infusions)
Number of subjects: 24
Study: 33038504

Group type: EXPERIMENTAL
Intervention: Facilitated extinction (FE) intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard (cognitive-behavioral) intervention
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Immediate transition to very low nicotine content (VLNC) cigarettes
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Gradual transition to very low nicotine content (VLNC) cigarettes
Number of subjects: 208
Study: 35711442

Group type: EXPERIMENTAL
Intervention: bivalent Oral Poliovirus Vaccine (bOPV)
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1115
Study: 33550679

Group type: EXPERIMENTAL
Intervention: Preparation for the TSST‐M alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Preparation for the TSST‐M with a parent
Number of subjects: 180

Group type: COMPARATOR
Intervention: No-stress control group
Number of subjects: 180
Study: 32114186

Group type: EXPERIMENTAL
Intervention: Enhanced treatment (5 worksites; n = 50 participants)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Minimal treatment (3 worksites; n = 47 participants)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both enhanced and minimal treatment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Enhanced treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Minimal treatment
Number of subjects: 97
Study: 36463145

Group type: EXPERIMENTAL
Intervention: Piezosurgery assisted osteotomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional drills
Number of subjects: 12
Study: 34337726

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV 30 min before surgery and then 40 mg IV every 12 h for the initial 48 h postoperatively (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline, n=20)
Number of subjects: 40
Study: 33371755

Group type: EXPERIMENTAL
Intervention: Group A: Urinary bladders transected cranial to the ureteral papillae and concomitantly omentalized
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Group B: Omentalization two weeks prior to vesicle creation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Group C: Neoureterocystostomy and omentalization followed by neoreservoir formation and tube cystostomy 2 weeks later
Number of subjects: 9
Study: 32030695

Group type: EXPERIMENTAL
Intervention: Vibrating tourniquet applied
Number of subjects: 90

Group type: COMPARATOR
Intervention: No vibrating tourniquet applied (control)
Number of subjects: 90
Study: 35711611

Group type: EXPERIMENTAL
Intervention: ERAS program
Number of subjects: 646

Group type: COMPARATOR
Intervention: Traditional group
Number of subjects: 646
Study: 34423039

Group type: EXPERIMENTAL
Intervention: HIV testing services
Number of subjects: 277

Group type: COMPARATOR
Intervention: Completed primary education
Number of subjects: 277

Group type: COMPARATOR
Intervention: Employment status
Number of subjects: 277

Group type: COMPARATOR
Intervention: Condom use in last sexual intercourse
Number of subjects: 277

Group type: COMPARATOR
Intervention: Involvement in HIV testing outreaches
Number of subjects: 277
Study: 33164085

Group type: EXPERIMENTAL
Intervention: Auricular percutaneous electrical nerve field stimulation (PENFS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 21
Study: 33213459

Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 12391

Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights
Number of subjects: 12391

Group type: COMPARATOR
Intervention: Reference Intakes
Number of subjects: 12391

Group type: EXPERIMENTAL
Intervention: Warning symbols
Number of subjects: 12391

Group type: EXPERIMENTAL
Intervention: Health Star Rating system
Number of subjects: 12391
Study: 33340845

Group type: EXPERIMENTAL
Intervention: External focus training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Internal focus training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 32315553

Group type: EXPERIMENTAL
Intervention: Wii-Fit training at home for additional 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Habitual activity during the 8-week follow-up
Number of subjects: 40
Study: 35997619

Group type: EXPERIMENTAL
Intervention: Self-management program (8 sessions)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 34618601

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus Venetoclax
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 32307641

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration cytology (FNAC)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Watchful observation
Number of subjects: 314
Study: 33945983

Group type: EXPERIMENTAL
Intervention: Feedback-informed treatment (FIT)
Number of subjects: 2233

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2233
Study: 32305659

Group type: EXPERIMENTAL
Intervention: Mindfulness session
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mind wandering (control condition)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mindfulness and Mind wandering (both groups)
Number of subjects: 80
Study: 32560970

Group type: EXPERIMENTAL
Intervention: Freeze-only ET
Number of subjects: 391

Group type: COMPARATOR
Intervention: Fresh ET
Number of subjects: 391
Study: 35325562

Group type: EXPERIMENTAL
Intervention: Remote telemonitoring (RTM) using an interactive bidirectional system (Motiva®)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Remote telemonitoring (RTM)
Number of subjects: 621
Study: 32386407

Group type: COMPARATOR
Intervention: Stepped-wedge cluster randomized trial (SW-CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional parallel cluster randomized trial (parallel-CRT)
Number of subjects: 0
Study: 35407572

Group type: EXPERIMENTAL
Intervention: Mosapride SR 15 mg combined with esomeprazole 20 mg once daily (ME group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg once daily alone (E group)
Number of subjects: 60
Study: 33201741

Group type: EXPERIMENTAL
Intervention: Patient-activation tools (3-minute video and 1-page checklist) delivered electronically 1 week, 3 days, and 24 hours prior to clinic visit
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study: 35761406

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valganciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TB-T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TB-T plus Valganciclovir
Number of subjects: 0
Study: 35124474

Group type: EXPERIMENTAL
Intervention: Multi-layer silicone-adhesive polyurethane foam dressing
Number of subjects: 709

Group type: COMPARATOR
Intervention: Standard preventive care alone
Number of subjects: 709
Study: 32062494

Group type: COMPARATOR
Intervention: PG54 (n = 434), administered prostaglandin F2α (25 mg im) 7 days prior to TAI
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: PG72 (n = 426), same treatment as PG54 but TAI performed 72 ± 2 h after CIDR removal
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: PG-CIDR54 (n = 422), same as PG54 but CIDR insert on Day -14
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: PG-CIDR72 (n = 418), same as PG-CIDR54 but TAI performed 72 ± 2 h after CIDR removal
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: PG72
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: PG-CIDR54
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: PG-CIDR72
Number of subjects: 1700

Group type: COMPARATOR
Intervention: PG54
Number of subjects: 1700
Study: 35788519

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 34112285

Group type: EXPERIMENTAL
Intervention: Low MAP group (LS group)
Number of subjects: 208

Group type: COMPARATOR
Intervention: High MAP group (HS group)
Number of subjects: 208
Study: 32759239

Group type: EXPERIMENTAL
Intervention: PFMT
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PFMT with biofeedback
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PFMT and rTMS
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PFMT with biofeedback and rTMS
Number of subjects: 176
Study: 35790835

Group type: EXPERIMENTAL
Intervention: AI-supported fluid quantifications
Number of subjects: 290

Group type: COMPARATOR
Intervention: Conventional qualitative assessments (state-of-the-art disease management)
Number of subjects: 290
Study: 35507901

Group type: EXPERIMENTAL
Intervention: IO bleaching only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IO immediately after MA (IMA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IO seven days after MA (7MA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: no treatment (NC)
Number of subjects: 40
Study: 32903044

Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ablation (NYHA I/II)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 363
Study: 34358675

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 1135
Study: 32368935

Group type: COMPARATOR
Intervention: BTB ACLR (Bone-Patellar Tendon-Bone Anterior Cruciate Ligament Reconstruction)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BTB ACLR with LET (Lateral Extra-articular Tenodesis)
Number of subjects: 120

Group type: COMPARATOR
Intervention: BTB ACLR
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BTB ACLR with LET
Number of subjects: 120
Study: 34989143

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 39
Study: 33588856

Group type: EXPERIMENTAL
Intervention: CYP2C8*2 or CYP2C8*3 allele carriers
Number of subjects: 618

Group type: COMPARATOR
Intervention: CYP2C8*1/*1 wild type homozygotes
Number of subjects: 618
Study: 32141968

Group type: EXPERIMENTAL
Intervention: Mid-trimester blood pressure trajectory parameters
Number of subjects: 3524
Study: 35867584

Group type: EXPERIMENTAL
Intervention: Ankle-worn accelerometer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower back, hip, thigh, and ankle accelerometers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Wrist accelerometer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thigh and ankle accelerometers
Number of subjects: 30
Study: 33293342

Group type: EXPERIMENTAL
Intervention: HPV-positive women (intervention)
Number of subjects: 1066

Group type: COMPARATOR
Intervention: HPV-positive/cytology-negative women (control)
Number of subjects: 1066
Study: 35704689

Group type: EXPERIMENTAL
Intervention: CBVR (Computer-Based Virtual Reality)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: PP (PowerPoint)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CBVR
Number of subjects: 68

Group type: COMPARATOR
Intervention: PP
Number of subjects: 68
Study: 32023544

Group type: EXPERIMENTAL
Intervention: ∼20‐min nap (N20)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ∼90‐min nap (N90)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal Sleep Night (NSN)
Number of subjects: 9
Study: 36094612

Group type: EXPERIMENTAL
Intervention: Tuli's Cheetah heel cup
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tuli's The X Brace
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 33612314

Group type: EXPERIMENTAL
Intervention: School-based sun protection program (SPP)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 376
Study: 32013799

Group type: EXPERIMENTAL
Intervention: Sleep duration <6 hours
Number of subjects: 2687

Group type: COMPARATOR
Intervention: Sleep duration 6-8 hours (reference)
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Sleep duration >8 hours
Number of subjects: 2687
Study: 33742738

Group type: EXPERIMENTAL
Intervention: QFR after DCB angioplasty
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Lesion length
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Vessel caliber lumen diameter
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: QFR cut-off value
Number of subjects: 208
Study: 34376401

Group type: EXPERIMENTAL
Intervention: CCP plus standard of care (SOC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 136
Study: 32183897

Group type: EXPERIMENTAL
Intervention: Structured implementation of the patient guideline using a multimodal strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual with awareness of the patient guideline
Number of subjects: 0
Study: 34618221

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise with breath-hold (IHG-BH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breath-hold (BH)
Number of subjects: 20
Study: 34800989

Group type: EXPERIMENTAL
Intervention: verum occipital tDCS treatment for 28 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: sham occipital tDCS treatment
Number of subjects: 24
Study: 32316911

Group type: EXPERIMENTAL
Intervention: Lovastatin (10 to 40 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 36148077

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - three 5-min cycles of inflation and deflation of blood pressure cuff on the upper limb
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 33531059

Group type: EXPERIMENTAL
Intervention: Met/Cyslow + PUFA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Met/Cyshigh + SFA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 33177731

Group type: EXPERIMENTAL
Intervention: Early interventional rehabilitation training (2-7 days after onset)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Delayed rehabilitation training (3-4 weeks after onset)
Number of subjects: 82
Study: 34857640

Group type: EXPERIMENTAL
Intervention: Prophylactic dextrose gel
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 165

Group type: COMPARATOR
Intervention: No gel (controls)
Number of subjects: 165
Study: 36150741

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% saline placebo
Number of subjects: 80
Study: 35966875

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg daily for 56 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33319932

Group type: EXPERIMENTAL
Intervention: Get going After concussIoN (novel behavioral intervention)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 42
Study: 34609058

Group type: EXPERIMENTAL
Intervention: Sandwich osteotomy with simultaneous implant placement using patient-specific guides (PSGs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional technique (free-hand sandwich osteotomy)
Number of subjects: 12
Study: 32239737

Group type: EXPERIMENTAL
Intervention: Nerve stimulator-guided injection with methylprednisolone/lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 20
Study: 35772449

Group type: EXPERIMENTAL
Intervention: PCV13 booster
Number of subjects: 261

Group type: COMPARATOR
Intervention: PHiD-CV10 booster
Number of subjects: 261
Study: 33740736

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel, applied twice weekly for 3 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional dressing with silver sulfadiazine ointment, applied twice daily
Number of subjects: 90
Study: 36039026

Group type: EXPERIMENTAL
Intervention: Scores of 4 to 8 points
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Scores >8 points
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Scores of 4 to 8 points in validation score (70%)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Scores >8 points in validation score (70%)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Individual recipient factors with 4 to 8 points
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Individual recipient factors with scores >8 points
Number of subjects: 932
Study: 32038000

Group type: EXPERIMENTAL
Intervention: Heat stress (HS) conditions (moderate THI = 81 to 83; severe THI = 88 to 90)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Thermoneutral (TN) conditions (ambient temperature 22°C for 7 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High THI levels
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low THI levels
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heat stress (HS) period
Number of subjects: 16
Study: 34538564

Group type: EXPERIMENTAL
Intervention: Elevation Training Mask® 2.0 (ETM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham control condition
Number of subjects: 10
Study: 36136304

Group type: EXPERIMENTAL
Intervention: Talazoparib + Temozolomide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Talazoparib + Irinotecan
Number of subjects: 40